Physician profile
Jonathan T Kim
NPI 1629281225
$6,086.78
in general payments reported to CMS, 2019-2025
10 companies · $595 in 2025
The $595 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,182 · 2020: $563 · 2021: $982 · 2022: $727 · 2023: $860 · 2024: $1,177 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.80 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,314.24 | 2019-2024 | Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $1,778.67 | 2021-2025 | |
| Novo Nordisk INC | $918.52 | 2019-2025 | Wegovy |
| Amgen INC. | $411.54 | 2024 | Krystexxa, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.42 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $171.14 | 2019-2024 | Jardiance, Trulicity, Mounjaro |
| Emd Serono, INC. | $84.40 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $56.82 | 2021-2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $35.14 | 2020-2022 | |
| Horizon Therapeutics Plc | $11.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.